SCHEMBL30280419

SCHEMBL30280419

CCOCc1c(I)c2cc(Br)cnc2n1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
ENPP3 O14638 1/20 0.37
ENPP1 P22413 1/20 0.37
NOD1 Q9Y239 2/20 0.36
NOD2 Q9HC29 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.35
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
POLB P06746 1/20 0.33
ALDH3A1 P30838 1/20 0.33
HTT P42858 1/20 0.33
CD4 P01730 2/20 0.32
PSEN1 P49768 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30280408 0.90 ENPP3 (0.38) KDM4EL3MBTL1LMNATSHRENPP3
SCHEMBL30280403 0.88 ENPP3 (0.40) KDM4EL3MBTL1LMNATSHRENPP3
SCHEMBL20502619 0.85 AGTR1 (0.42) KDM4EL3MBTL1LMNATSHRENPP3
SCHEMBL7513541 0.81 PTGDR2 (0.43) KDM4EL3MBTL1LMNATSHRENPP3
SCHEMBL31396603 0.81 MAPT (0.36) KDM4EL3MBTL1LMNATSHRENPP3
SCHEMBL30280480 0.79 ENPP3 (0.41) KDM4EL3MBTL1LMNAENPP3ENPP1
SCHEMBL30280475 0.79 ENPP3 (0.41) KDM4EL3MBTL1LMNAENPP3ENPP1
SCHEMBL30280386 0.78 ENPP3 (0.45) KDM4EL3MBTL1LMNATSHRENPP3
SCHEMBL30280425 0.77 ENPP3 (0.39) KDM4EL3MBTL1LMNATSHRENPP3
SCHEMBL31436003 0.73 MAPT (0.39) KDM4EL3MBTL1LMNATSHRPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 US disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH KDM4E 2957/4885L3MBTL1 1466/4885LMNA 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.